Our Leadership Team

Dean Park, CEO of Mezzion

Dean Park, CEO

Dean Park is the Founder, Chairman, and Chief Executive Officer of Mezzion Pharma Co., Ltd. and Mezzion Pharmaceuticals, Inc., where he leads the company’s long-term strategy and global growth. He has founded and served as CEO and/or President of multiple successful international companies across healthcare, investment and financial services. Earlier in his career, Dean held senior leadership roles in investment banking, including Vice President and Director positions within the investment banking group at Merrill Lynch Capital Markets. At Mezzion, he is focused on advancing late-stage development, building a sustainable rare-disease platform and positioning the company for long-term value creation.

red line wave graphics

Ridwan Shabsigh, MD, FACS, President & Chief Operating Officer

Ridwan Shabsigh, MD, FACS, brings more than 35 years of leadership experience across clinical research, drug development and commercialization. A globally recognized key opinion leader in the PDE5 inhibitor class, he has played a central role in the development and launch of multiple therapies in this category.across clinical research, drug development and commercialization. A globally recognized key opinion leader in the PDE5 inhibitor class, he has played a central role in the development and launch of multiple therapies in this category. As President and COO, Dr. Shabsigh oversees clinical development, medical strategy and operational execution with a focus on advancing JURVIGO® through the FUEL-2 trial and toward potential approval. He previously served as Chair of the Department of Surgery at SBH Health System and is a Full Professor of Clinical Urology at Weill Cornell Medicine.

John Presser, MBA

John Presser, EVP, Chief Business Officer

John Presser leads global business development, commercial strategy, and external affairs at Mezzion. He plays a key role in aligning late-stage R&D with launch execution, while expanding the company’s rare disease pipeline and strategic partnerships. Prior to Mezzion, he spent nearly 20 years at Boehringer Ingelheim, where he led the largest U.S. payer portfolio and supported the launch of 30+ products, including 10 global blockbusters. He began his career in R&D at Amylin Pharmaceuticals and The Salk Institute.